<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00355615</url>
  </required_header>
  <id_info>
    <org_study_id>D3561C00087</org_study_id>
    <secondary_id>PLUTO</secondary_id>
    <nct_id>NCT00355615</nct_id>
  </id_info>
  <brief_title>PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin</brief_title>
  <official_title>A Phase IIIb, Efficacy, and Safety Study of Rosuvastatin in Children 10-17 Years of Age With Heterozygous Familial Hypercholesterolemia: a 12-week, Double-blind, Randomized, Multicenter, Placebo-controlled Study With a 40-week, Open-label, Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the efficacy of once-daily rosuvastatin
      in reducing LDL-C in children and adolescents aged 10-17 years with HeFH from baseline (Day
      0) to the end of the 12-week double-blind treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline (Day 0) to the End of the 12-week Double-blind Treatment Phase</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change in low-density lipoprotein cholesterol (LDL-C) = (final value - Baseline value)/Baseline value * 100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in LDL-C and Other Lipid Parameters From Baseline to Week 6, and at End of Double-blind Dose Treatment Phase (Week 12)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percent change from baseline in LDL-C after six week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Control Rate Based on Achievement of LDL-C Target of &lt;110 mg/dL During Double-blind Dose Treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent of patients achieving LDL-C &lt; 110 mg/dL out of the total patients in each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in HDL-C</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Percent change in high-density lipoprotein cholesterol (HDL-C) after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Non-HDL-C at 12 Weeks</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Percent change in non-HDL-C at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Triglycerides (TG)</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Percent change in tryglycerides (TG) after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Cholesterol (TC)</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Percent change from baseline in total cholesteral after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Apolipoprotein A-1 (ApoA-1)</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Percent change in ApoA-1 after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Apolipoprotein B (ApoB)</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Percent change in ApoB after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in ApoB/ApoA-1</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Percent change in the ratio of ApoB/ApoA-1 after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in LDL-C/HDL-C</measure>
    <time_frame>After 12 week of treatment</time_frame>
    <description>Percent change in the ratio of LDL-C/HDL-C after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in TC/HDL-C</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Percent change in the ratio of TC/HDL-C after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Non-HDL-C/HDL-C</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Percent change in the ratio of non-HDL-C/HDL-C after 12 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">173</enrollment>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>rosuva 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rosuvastatin 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rosuva 10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rosuvastatin 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rosuva 20</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rosuvastatin 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rosuva ol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>rosuvastatin open label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>oral</description>
    <arm_group_label>rosuva 5</arm_group_label>
    <arm_group_label>rosuva 10</arm_group_label>
    <arm_group_label>rosuva 20</arm_group_label>
    <arm_group_label>rosuva ol</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female (at least 1 year post-menarche) children and adolescents (aged 10 -17
             years) with heterozygous familial hypercholesterolemia (HeFH)

        Exclusion Criteria:

          -  Certain medical conditions and lab test results

          -  History of a reaction to rosuvastatin or other statin drugs

          -  Use of specified disallowed medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Crestor Medical Science Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sherbrook</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research SIte</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research SIte</name>
      <address>
        <city>Waalwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reus</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2006</study_first_submitted>
  <study_first_submitted_qc>July 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2006</study_first_posted>
  <results_first_submitted>May 29, 2009</results_first_submitted>
  <results_first_submitted_qc>May 29, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 20, 2009</results_first_posted>
  <last_update_submitted>August 29, 2011</last_update_submitted>
  <last_update_submitted_qc>August 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heterozygous Familial Hypercholesterolemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One-hundred male and female (Tanner stages II to V, at least 1 year post-menarche) children and adolescents (aged 10 to 17 years with Heterozygous familial hypercholesterolemia were randomized into the study, from 20 sites located in The United States (3 sites), The Netherlands (7 sites), Norway (1 site), Spain (3 sites), and Canada (6 sites).</recruitment_details>
      <pre_assignment_details>Patients entered a 6 week dietary lead-in/drug washout period. Eligible patients were then randomly assigned to double-blind treatment with rosuvastatin 5 mg, 10 mg, 20 mg, or matching placebo, administered orally once daily for 12 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rosuva 5</title>
          <description>rosuvastatin 5 mg</description>
        </group>
        <group group_id="P2">
          <title>Rosuva 10</title>
          <description>rosuvastatin 10 mg</description>
        </group>
        <group group_id="P3">
          <title>Rosuva 20</title>
          <description>rosuvastatin 20 mg</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>placebo</description>
        </group>
        <group group_id="P5">
          <title>Rosuva ol</title>
          <description>rosuvastatin open label</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized Double Blind Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="46"/>
                <participants group_id="P5" count="0">open label phase followed the randomized phase</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41">1 dropped out due to adverse event</participants>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="44">45 were randomized but 1 never received drug</participants>
                <participants group_id="P4" count="45">1 dropped out due to an adverse event</participants>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>40-week Rosuvastatin Open Label Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="173"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>investigational site closed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rosuva 5</title>
          <description>rosuvastatin 5 mg</description>
        </group>
        <group group_id="B2">
          <title>Rosuva 10</title>
          <description>rosuvastatin 10 mg</description>
        </group>
        <group group_id="B3">
          <title>Rosuva 20</title>
          <description>rosuvastatin 20 mg</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="45"/>
            <count group_id="B4" value="46"/>
            <count group_id="B5" value="177"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.1" lower_limit="10" upper_limit="17"/>
                    <measurement group_id="B2" value="14.5" lower_limit="11" upper_limit="17"/>
                    <measurement group_id="B3" value="14.2" lower_limit="11" upper_limit="17"/>
                    <measurement group_id="B4" value="14.3" lower_limit="10" upper_limit="17"/>
                    <measurement group_id="B5" value="14.3" lower_limit="10" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline low-density lipoprotein cholesterol (LDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="237.70" spread="55.06"/>
                    <measurement group_id="B2" value="229.10" spread="44.70"/>
                    <measurement group_id="B3" value="237.40" spread="47.80"/>
                    <measurement group_id="B4" value="229.00" spread="43.13"/>
                    <measurement group_id="B5" value="233.3" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline (Day 0) to the End of the 12-week Double-blind Treatment Phase</title>
        <description>Percent change in low-density lipoprotein cholesterol (LDL-C) = (final value - Baseline value)/Baseline value * 100</description>
        <time_frame>12 weeks</time_frame>
        <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuva 5</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuva 10</title>
            <description>rosuvastatin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Rosuva 20</title>
            <description>rosuvastatin 20 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline (Day 0) to the End of the 12-week Double-blind Treatment Phase</title>
          <description>Percent change in low-density lipoprotein cholesterol (LDL-C) = (final value - Baseline value)/Baseline value * 100</description>
          <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.5" spread="11.38"/>
                    <measurement group_id="O2" value="-44.4" spread="12.15"/>
                    <measurement group_id="O3" value="-50.2" spread="13.3"/>
                    <measurement group_id="O4" value="-0.5" spread="13.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in LDL-C and Other Lipid Parameters From Baseline to Week 6, and at End of Double-blind Dose Treatment Phase (Week 12)</title>
        <description>Percent change from baseline in LDL-C after six week of treatment</description>
        <time_frame>6 weeks</time_frame>
        <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuva 5</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuva 10</title>
            <description>rosuvastatin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Rosuva 20</title>
            <description>rosuvastatin 20 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in LDL-C and Other Lipid Parameters From Baseline to Week 6, and at End of Double-blind Dose Treatment Phase (Week 12)</title>
          <description>Percent change from baseline in LDL-C after six week of treatment</description>
          <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.3" spread="12.22"/>
                    <measurement group_id="O2" value="-45.2" spread="11.15"/>
                    <measurement group_id="O3" value="-50.0" spread="11.42"/>
                    <measurement group_id="O4" value="-0.6" spread="13.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Control Rate Based on Achievement of LDL-C Target of &lt;110 mg/dL During Double-blind Dose Treatment</title>
        <description>Percent of patients achieving LDL-C &lt; 110 mg/dL out of the total patients in each treatment group</description>
        <time_frame>12 weeks</time_frame>
        <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuva 5</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuva 10</title>
            <description>rosuvastatin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Rosuva 20</title>
            <description>rosuvastatin 20 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Control Rate Based on Achievement of LDL-C Target of &lt;110 mg/dL During Double-blind Dose Treatment</title>
          <description>Percent of patients achieving LDL-C &lt; 110 mg/dL out of the total patients in each treatment group</description>
          <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9"/>
                    <measurement group_id="O2" value="40.9"/>
                    <measurement group_id="O3" value="40.9"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in HDL-C</title>
        <description>Percent change in high-density lipoprotein cholesterol (HDL-C) after 12 weeks of treatment</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuva 5</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuva 10</title>
            <description>rosuvastatin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Rosuva 20</title>
            <description>rosuvastatin 20 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in HDL-C</title>
          <description>Percent change in high-density lipoprotein cholesterol (HDL-C) after 12 weeks of treatment</description>
          <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="15.53"/>
                    <measurement group_id="O2" value="10.1" spread="14.19"/>
                    <measurement group_id="O3" value="8.9" spread="14.11"/>
                    <measurement group_id="O4" value="7.6" spread="17.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Non-HDL-C at 12 Weeks</title>
        <description>Percent change in non-HDL-C at 12 weeks</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuva 5</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuva 10</title>
            <description>rosuvastatin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Rosuva 20</title>
            <description>rosuvastatin 20 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Non-HDL-C at 12 Weeks</title>
          <description>Percent change in non-HDL-C at 12 weeks</description>
          <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.3" spread="9.98"/>
                    <measurement group_id="O2" value="-42.8" spread="11.50"/>
                    <measurement group_id="O3" value="-47.7" spread="13.50"/>
                    <measurement group_id="O4" value="-0.8" spread="11.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Triglycerides (TG)</title>
        <description>Percent change in tryglycerides (TG) after 12 weeks of treatment</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuva 5</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuva 10</title>
            <description>rosuvastatin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Rosuva 20</title>
            <description>rosuvastatin 20 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Triglycerides (TG)</title>
          <description>Percent change in tryglycerides (TG) after 12 weeks of treatment</description>
          <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="49.07"/>
                    <measurement group_id="O2" value="-14.2" spread="29.66"/>
                    <measurement group_id="O3" value="-7.9" spread="55.88"/>
                    <measurement group_id="O4" value="3.4" spread="48.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Cholesterol (TC)</title>
        <description>Percent change from baseline in total cholesteral after 12 weeks of treatment</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuva 5</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuva 10</title>
            <description>rosuvastatin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Rosuva 20</title>
            <description>rosuvastatin 20 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Cholesterol (TC)</title>
          <description>Percent change from baseline in total cholesteral after 12 weeks of treatment</description>
          <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.0" spread="9.63"/>
                    <measurement group_id="O2" value="-34.1" spread="9.5"/>
                    <measurement group_id="O3" value="-38.9" spread="12.08"/>
                    <measurement group_id="O4" value="0.2" spread="10.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Apolipoprotein A-1 (ApoA-1)</title>
        <description>Percent change in ApoA-1 after 12 weeks of treatment</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuva 5</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuva 10</title>
            <description>rosuvastatin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Rosuva 20</title>
            <description>rosuvastatin 20 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Apolipoprotein A-1 (ApoA-1)</title>
          <description>Percent change in ApoA-1 after 12 weeks of treatment</description>
          <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
          <units>mean percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="9.69"/>
                    <measurement group_id="O2" value="4.3" spread="9.85"/>
                    <measurement group_id="O3" value="3.9" spread="10.68"/>
                    <measurement group_id="O4" value="3.6" spread="15.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Apolipoprotein B (ApoB)</title>
        <description>Percent change in ApoB after 12 weeks of treatment</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuva 5</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuva 10</title>
            <description>rosuvastatin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Rosuva 20</title>
            <description>rosuvastatin 20 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Apolipoprotein B (ApoB)</title>
          <description>Percent change in ApoB after 12 weeks of treatment</description>
          <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
          <units>mean percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.1" spread="9.13"/>
                    <measurement group_id="O2" value="-37.8" spread="11.75"/>
                    <measurement group_id="O3" value="-40.7" spread="13.91"/>
                    <measurement group_id="O4" value="-1.5" spread="14.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in ApoB/ApoA-1</title>
        <description>Percent change in the ratio of ApoB/ApoA-1 after 12 weeks of treatment</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuva 5</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuva 10</title>
            <description>rosuvastatin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Rosuva 20</title>
            <description>rosuvastatin 20 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in ApoB/ApoA-1</title>
          <description>Percent change in the ratio of ApoB/ApoA-1 after 12 weeks of treatment</description>
          <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
          <units>mean percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.1" spread="9.99"/>
                    <measurement group_id="O2" value="-40.0" spread="12.06"/>
                    <measurement group_id="O3" value="-42.8" spread="12.23"/>
                    <measurement group_id="O4" value="-3.4" spread="16.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in LDL-C/HDL-C</title>
        <description>Percent change in the ratio of LDL-C/HDL-C after 12 weeks of treatment</description>
        <time_frame>After 12 week of treatment</time_frame>
        <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuva 5</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuva 10</title>
            <description>rosuvastatin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Rosuva 20</title>
            <description>rosuvastatin 20 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in LDL-C/HDL-C</title>
          <description>Percent change in the ratio of LDL-C/HDL-C after 12 weeks of treatment</description>
          <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
          <units>mean percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.4" spread="11.36"/>
                    <measurement group_id="O2" value="-48.6" spread="13.26"/>
                    <measurement group_id="O3" value="-53.6" spread="12.85"/>
                    <measurement group_id="O4" value="-5.5" spread="17.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in TC/HDL-C</title>
        <description>Percent change in the ratio of TC/HDL-C after 12 weeks of treatment</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuva 5</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuva 10</title>
            <description>rosuvastatin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Rosuva 20</title>
            <description>rosuvastatin 20 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in TC/HDL-C</title>
          <description>Percent change in the ratio of TC/HDL-C after 12 weeks of treatment</description>
          <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
          <units>mean percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.1" spread="10.72"/>
                    <measurement group_id="O2" value="-39.3" spread="11.55"/>
                    <measurement group_id="O3" value="-43.2" spread="11.76"/>
                    <measurement group_id="O4" value="-5.2" spread="15.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Non-HDL-C/HDL-C</title>
        <description>Percent change in the ratio of non-HDL-C/HDL-C after 12 weeks of treatment</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuva 5</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuva 10</title>
            <description>rosuvastatin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Rosuva 20</title>
            <description>rosuvastatin 20 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Non-HDL-C/HDL-C</title>
          <description>Percent change in the ratio of non-HDL-C/HDL-C after 12 weeks of treatment</description>
          <population>Intention-to-treat (ITT) analysis set included all randomized patients who took study medication and had both a baseline reading and at least 1 post-baseline reading for the variable being analyzed. Analyses were performed using the last-observation-carried-forward (LOCF) method on the ITT analysis set for all efficacy outcome variables.</population>
          <units>mean percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.9" spread="12.12"/>
                    <measurement group_id="O2" value="-47.1" spread="13.12"/>
                    <measurement group_id="O3" value="-51.2" spread="13.18"/>
                    <measurement group_id="O4" value="-5.8" spread="17.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rosuva 5</title>
          <description>rosuvastatin 5 mg</description>
        </group>
        <group group_id="E2">
          <title>Rosuva 10</title>
          <description>rosuvastatin 10 mg</description>
        </group>
        <group group_id="E3">
          <title>Rosuva 20</title>
          <description>rosuvastatin 20 mg</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>placebo</description>
        </group>
        <group group_id="E5">
          <title>Rosuva ol</title>
          <description>rosuvastatin open label</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
                <counts group_id="E2" subjects_affected="0"/>
                <counts group_id="E3" subjects_affected="0"/>
                <counts group_id="E4" subjects_affected="1"/>
                <counts group_id="E5" subjects_affected="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash Vesicular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12"/>
                <counts group_id="E2" subjects_affected="14"/>
                <counts group_id="E3" subjects_affected="17"/>
                <counts group_id="E4" subjects_affected="17"/>
                <counts group_id="E5" subjects_affected="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>AZTrial_Results_Posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

